References
- Vaux DL, Cory S, Adams JM. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 1988;335:440–442.
- Schmitt CA, Rosenthal CT, Lowe SW. Genetic analysis of chemoresistance in primary murine lymphomas. Nat Med 2000;6: 1029–1035.
- Adams JM, Cory S. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 2007;26:1324–1337.
- Del Gaizo Moore V, Brown JR, Certo M, . Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. J Clin Invest 2007;117: 112–121.
- Chen L, Willis SN, Wei A, . Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell 2005;17:393–403.
- O’Brien SM, Cunningham CC, Golenkov AK, . Phase I to II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in patients with advanced chronic lymphocytic leukemia. J Clin Oncol 2005;23:7697–7702.
- van Delft MF, Wei AH, Mason KD, . The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 2006;10:389–399.
- Lessene G, Czabotar PE, Colman PM. BCL-2 family antagonists for cancer therapy. Nat Rev Drug Discov 2008;7:989–1000.
- Balakrishnan K, Aggarwal S, Wierda W, . Bax and Bak are required for apogossypolone, a BH3-mimetic, induced apoptosis in chronic lymphocytic leukemia cells. Leuk Lymphoma 2013;54:1098–1101.
- James DF, Castro JE, Loria O, . AT-101, a small molecule Bcl-2 antagonist, in treatment naive CLL patients (pts) with high risk features; preliminary results from an ongoing phase I trial. J Clin Oncol 2006;24(18 Suppl.): Abstract 6605.
- Kitada S, Kress CL, Krajewska M, . Bcl-2 antagonist apogossypol (NSC736630) displays single-agent activity in Bcl-2-transgenic mice and has superior efficacy with less toxicity compared with gossypol (NSC19048). Blood 2008;111:3211–3219.
- O’Brien SM, Claxton DF, Crump M, . Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia. Blood 2009;113:299–305.
- Oltersdorf T, Elmore SW, Shoemaker AR, . An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005;435:677–681.
- Mason KD, Khaw SL, Rayeroux KC, . The BH3 mimetic compound, ABT-737, synergizes with a range of cytotoxic chemotherapy agents in chronic lymphocytic leukemia. Leukemia 2009;23:2034–2041.
- Roberts AW, Seymour JF, Brown JR, . Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. J Clin Oncol 2012;30:488–496.
- Mason KD, Carpinelli MR, Fletcher JI, . Programmed anuclear cell death delimits platelet life span. Cell 2007;128:1173–1186.
- Souers AJ, Leverson JD, Boghaert ER, . ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 2013 Jan 6. [Epub ahead of print]
- Billard C. Design of novel BH3 mimetics for the treatment of chronic lymphocytic leukemia. Leukemia 2012;26:2032–2038.
- Merino D, Khaw SL, Glaser SP, . Bcl-2, Bcl-x(L), and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cells. Blood 2012;119:5807–5816.
- Doi K, Li R, Sung SS, . Discovery of marinopyrrole A (maritoclax) as a selective Mcl-1 antagonist that overcomes ABT-737 resistance by binding to and targeting Mcl-1 for proteasomal degradation. J Biol Chem 2012;287:10224–10235.